SEC Form 4 · accession 0001567619-19-000988
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Jan 8, 2019
Accepted (ET)
Jan 10, 2019 · 6:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 8, 2019 | M | 6,000 | $14.39 | A | 294,290 | D | |
| Common StockF1,F2 | Jan 8, 2019 | S | 1,000 | $91.144 | D | 293,290 | D | |
| Common StockF1,F3 | Jan 8, 2019 | S | 1,599 | $91.55 | D | 291,691 | D | |
| Common StockF1,F4 | Jan 8, 2019 | S | 3,401 | $91.7348 | D | 288,290 | D | |
| Common Stock | holding | — | — | — | 181,501 | I | Shares held by Jean-Jacques Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F5 | $14.39 | Jan 8, 2019 | M | 6,000 | D | Nov 12, 2009 | May 11, 2019 | Common Stock | 6,000 | 83,000 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on November 15, 2018.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $90.51 to $91.45. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F3The price in column 4 is the weighted average price. The price actually received ranged from $91.51 to $91.60. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F4The price in column 4 is the weighted average price. The price actually received ranged from $91.61 to $92.22. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F5Reflects the number of options outstanding after the transactions from this specific stock option grant.